Page 66 - Haematologica Vol. 110 - January 2025

ARTICLE - Real-life study on 421 adult Ph-neg ALL treated with LAL1913 program D. Lazzarotto et al. Table 1. Characteristics of the 421 study patients.
Characteristics
All patients N=421
B-ALL/LL N=221
T-ALL/LL N=200
Age in years, median (range) ≤40, N (%)
41-55, N (%)
>55, N (%)
42.0 (18-80) 199 (47) 125 (30) 97 (23)
45.0 (18-80) 87 (39) 66 (30) 68 (31)
38.5 (18-72) 112 (56) 59 (29.5) 29 (14.5)
Male, N (%)
248 (59)
111 (50)
137 (68.5)
Diagnosis, N (%) ALL
LL
371 (88) 50 (12)
216 (98) 5 (2)
155 (77.5) 45 (22.5)
ECOG PS, N 0;1;2;3;4;NA
212;147;42;15;3;2
122;77;19;3;0;0
90;70;23;12;3;2
Hemoglobin g/dL, median (range)
10.7 (4.1-17.2)
9.3 (4.1-15.1)
12.3 (4.2-17.2)
WBC x109/L, median (range) ≤30, N (%)
31-100, N (%)
>100, N (%)
9.9 (0.2-626.9) 304 (72)
66 (16)
51 (12)
6.9 (0.2-626.9) 170 (77)
31 (14)
20 (9)
12.2 (0.5-538.0) 134 (67)
35 (17.5)
31 (15.5)
PB blasts %, median (range)
38.0 (0.0-100.0)
40.5 (0.0-100.0)
30.0 (0.0-100.0)
BM blasts %, median (range)
80.0 (0.0-100.0)
85.0 (0.0-100.0)
73.0 (0.0-100.0)
Platelets x109/L, median (range)
78 (4-753)
63.5 (8-400)
115 (4-753)
Hepatomegaly, N (%)
27 (6)
12 (5)
15 (7.5)
Splenomegaly, N (%)
44 (10.5)
18 (8)
26 (13)
Lymphadenopathy, N (%)
110 (26)
26 (12)
84 (42)
Mediastinal mass, N (%)
96 (23)
2 (1)
94 (47)
CNS involvement, N (%)
37 (9)
12 (5)
25 (12.5)
Other involved sites, N (%) testis/ovary:skin
5 1:4
-
-
Immunophenotype, N (%)
B: pro, common, pre, MPAL, UND
T: ETP, pro, pre, cortical, mature, MPAL, UND
221 (52.5) 200 (47.5)
39,130,23,5,24 -
- 40,15,23,57,13,4,48
Cytogenetics/genetics, N (%) Evaluable
Normal Adverse
t(4;11)/KMT2A::AFF4, t(11;19)
Othera Non-adverse
t(1;19)/E2A::PBX1 Hyperdiploid
Other non-adverse
342 (81.2) 174 (51) 60 (17) 15
45 108 (32) 5
15
88
191 (86.4) 78
45
15
30
67
5
15
48
151 (75.5) 96
15
-
15
40
0- 40
Risk stratification, N (%) Evaluable
Standard risk High risk Very high risk
420/421 (99.8) 207 (49)
42 (10) 171 (41)
221/221 (100) 120 (54) 34 (15)
67 (30)
199/200 (99.5) 87 (44)
8 (4)
104 (52)
ALL: acute lymphoblastic leukemia; LL: lymphoblastic lymphoma; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NA: not available; WBC: white blood cells; PB: peripheral blood; BM: bone marrow; CNS: central nervous system; MPAL: mixed-phenotype acute leukemia; UND: undefined; ETP: early T precursor. aOther than t(4;11)/KMT2A rearrangement: 11q23, +8, -7, del6q, t(8;14) abnormalities, low hypodiploidy (30-39 chromosomes), near triploidy (60-78 chromosomes) or complex karyotype with ≥5 unrelated anomalies.
Haematologica | 110 January 2025
58